Pneumococcal conjugate vaccines

Pediatric Infectious Disease Journal

Volumn 18, Issue 6, 1999, Pages 543-551

  Eskola, Juhani ^a   Anttila, Merja ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Conjugate vaccine; Pneumococcus; Streptococcus pneumoniae

Indexed keywords

CARRIER PROTEIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; POLYSACCHARIDE VACCINE; STREPTOCOCCUS VACCINE; TETANUS TOXOID;

DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHILD; CLINICAL TRIALS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOLOGIC MEMORY; INFANT; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0033001598     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199906000-00015     Document Type: Review

References (59)

1. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(RR-8):1-24.
2. Butler JC, Hoffman J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996;174:986-93.
3. Dagan R, Melamed R, Muallem M, et al. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci durig the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996;174:1352-5.
4. Jacobs MR. Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: overview and update. Pediatr Infect Dis J 1998;17:947-52.
5. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165(Suppl 1):S49-52.
6. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980;152:361-76.
7. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985;314:537-9.
8. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994;265:1385-7.
9. Sniadak DH, Schwartz B, Lipman H, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children: implications for vaccine strategies. Pediatr Infect Dis J 1995;14:503-10.
10. Karma P, Pukander J, Sipilä M, et al. Prevention of otitis media in children by pneumococcal vaccination. Am J Otolaryngol 1985;8:173-84.
11. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin S, Orenstein W, eds. Vaccines. Philadelphia: Saunders, 1999:553-607.
12. Daum RS, Hogerman D, Rennels MB, et al. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 1997;176:445-55.
13. Frasch C. Haemophilus influenzae type b conjugate and combination vaccines. Clin Immunother 1995;4:376-86.
14. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101:604-11.
15. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996;173:83-90.
16. Powers DC, Anderson EL, Lottenbach K, Mink CA. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996;173:1014-8.
17. Käyhty H, Åhman H, Rönnberg PR, Tillikainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995;172:1273-8.
18. Åhman H, Käyhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996;15: 134-9.
19. Leach A, Ceesay SJ, Banya WA, Greenwood BM. Pilot trial of pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996;15: 333-9.
20. Sigurdardottir ST, Vidarsson G, Gudnason T, et al. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr Infect Dis J 1997;16:667-74.
21. Obaro SK, Huo Z, Banya WAS, et al. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr Infect Dis J 1997;16:1135-40.
22. Dagan R, Melamed R, Zamir O, Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 1997;16:1053-9.
23. Åhman H, Käyhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-16.
24. Sarnaik S, Kaplan J, Schiffman G, Bryla D, Robbins JB, Schneerson R. Studies on pneumococcus vaccine alone or mixed with DTP and on pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two-to five-year-old children with sickle cell anemia. Pediatr Infect Dis J 1990;9:181-6.
25. Molrine DC, George S, Tarbell N, et al. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med 1995;123: 828-34.
26. Vernaccio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998;133:275-8.
27. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996;173:256-8.
28. King JC, Vink PE, Farley JJ, Smilie M, Parks M, Lichenstein R. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997;99:575-80.
29. King JC, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency , virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15:192-6.
30. Sorensen RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998;17:685-91.
31. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996;128:649-53.
32. O'Brien KL, Steinhoff MC, Edwards K, Keyserling H, Thoms ML, Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 1996;15:425-30.
33. Vidarsson G, Sigurdardottir S, Gudnason T, et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998;66: 2866-70.
34. Anttila M, Eskola J, Käyhty H. Opsonic activity and concentration of antibodies to Streptococcus pneumoniae type 6B [Abstract 599]. In: 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, September, 1997. Washington, DC: Infectious Diseases Society of America, 1997.
35. Anttila M, Eskola J, Åhman H, Käyhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999;17: 1970-7.
36. Anttila M, Eskola J, Åhman H, Käyhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998; 177:1614-21.
37. Soininen A, Seppälä I, Nieminen T, Eskola J, Käyhty H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 1999;17:1889-97.
38. Anttila M, Soininen A, Nieminen T, Jäntti V, Eskola J, Käyhty H. Contribution of serotype specific IgG concentration, subclass ratio, and relative avidity to opsonophagocytic activity against Streptococcus pneumoniae [Abstract 58]. In: Pneumococcal Vaccines for the World Conference, Washington, DC, October 12 to 14, 1998.
39. Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann NY Acad Sci 1995;754:35-67.
40. Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 1999;17:126-33.
41. Åhman H, Käyhty H, Leroy O, Froeschle J, Eskola J. Immunogenicity of octavalent pneumococcal (Pnc) conjugate vaccines (PncD, PncT) in Finnish infants [Abstract]. In: 36th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, September, 1996. Washington, DC: Infectious Diseases Society of America, 1996.
42. Ahman H, Käyhty H, Eskola J. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. In: 15th Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Paris, France, May, 1997.
43. Wuorimaa T, Käyhty H, Jancu J, et al. Tolerability and immunogenicity of eleven-valent pneumococcal conjugate vaccine in healthy toddlers. [Abstract 47]. In: Pneumococcal Vaccines for the World Conference, Washington, DC, October 12 to 14, 1998.
44. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998; 66:2093-8.
45. Lieberman JM, Greenberg DP, Wong VK, et al. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b. J Pediatr 1995;126:198-205.
46. Takala AK, Eskola J, Leinonen M, et al. Reduction in oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991;164:982-6.
47. Giebink GS, Koskela M, Vella PP et al. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 1993; 167:347-55.
48. Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high risk children. J Pediatr 1993;123:801-10.
49. Nieminen T, Käyhty H, Virolainen A, Eskola J. Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 1998;16:313-9.
50. Lue C, Prince SJ, Fattom A, Schneerson R, Robbins JB, Mestecky J. Antibody-secreting peripheral blood lymphocytes induced by immunization with a conjugate consisting of Streptococcus pneumoniae type 12F polysaccharide and diphtheria toxoid. Infect Immun 1990;58:2547-54.
51. Nieminen T, Eskola J, Käyhty H. Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine 1998;16:630-6.
52. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
53. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;16:1060-4.
54. Obaro SK, Adegbola RA, Banya WAS, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996;348:271-2.
55. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 1997;94:6571-6.
56. Eskola J, Takala AK, Kilpi TM, Lankinen KS, Käyhty H. Clinical evaluation of new pneumococcal vaccines: the Finnish approach. Dev Biol Stand 1998;95:85-92.
57. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37 000 infants and children: results of the Northern California Kaiser Permanente efficacy trial [Abstract LB-9]. In: 38th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Diego, CA, September, 1998.
58. Moxon ER. Natural history and pathogenesis as they affect clinical trials. Dev Biol Stand 1998;95:61-7.
59. Coffey TJ, Enright MC, Daniels M, et al. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae. Mol Microbiol 1998;27:73-83.